Cargando…
Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist
In this study, we present the translational modeling used in the discovery of AZD1979, a melanin‐concentrating hormone receptor 1 (MCHr1) antagonist aimed for treatment of obesity. The model quantitatively connects the relevant biomarkers and thereby closes the scaling path from rodent to man, as we...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529746/ https://www.ncbi.nlm.nih.gov/pubmed/28556607 http://dx.doi.org/10.1002/psp4.12199 |
_version_ | 1783253177181667328 |
---|---|
author | Gennemark, P Trägårdh, M Lindén, D Ploj, K Johansson, A Turnbull, A Carlsson, B Antonsson, M |
author_facet | Gennemark, P Trägårdh, M Lindén, D Ploj, K Johansson, A Turnbull, A Carlsson, B Antonsson, M |
author_sort | Gennemark, P |
collection | PubMed |
description | In this study, we present the translational modeling used in the discovery of AZD1979, a melanin‐concentrating hormone receptor 1 (MCHr1) antagonist aimed for treatment of obesity. The model quantitatively connects the relevant biomarkers and thereby closes the scaling path from rodent to man, as well as from dose to effect level. The complexity of individual modeling steps depends on the quality and quantity of data as well as the prior information; from semimechanistic body‐composition models to standard linear regression. Key predictions are obtained by standard forward simulation (e.g., predicting effect from exposure), as well as non‐parametric input estimation (e.g., predicting energy intake from longitudinal body‐weight data), across species. The work illustrates how modeling integrates data from several species, fills critical gaps between biomarkers, and supports experimental design and human dose‐prediction. We believe this approach can be of general interest for translation in the obesity field, and might inspire translational reasoning more broadly. |
format | Online Article Text |
id | pubmed-5529746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55297462017-08-02 Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist Gennemark, P Trägårdh, M Lindén, D Ploj, K Johansson, A Turnbull, A Carlsson, B Antonsson, M CPT Pharmacometrics Syst Pharmacol Original Articles In this study, we present the translational modeling used in the discovery of AZD1979, a melanin‐concentrating hormone receptor 1 (MCHr1) antagonist aimed for treatment of obesity. The model quantitatively connects the relevant biomarkers and thereby closes the scaling path from rodent to man, as well as from dose to effect level. The complexity of individual modeling steps depends on the quality and quantity of data as well as the prior information; from semimechanistic body‐composition models to standard linear regression. Key predictions are obtained by standard forward simulation (e.g., predicting effect from exposure), as well as non‐parametric input estimation (e.g., predicting energy intake from longitudinal body‐weight data), across species. The work illustrates how modeling integrates data from several species, fills critical gaps between biomarkers, and supports experimental design and human dose‐prediction. We believe this approach can be of general interest for translation in the obesity field, and might inspire translational reasoning more broadly. John Wiley and Sons Inc. 2017-05-27 2017-07 /pmc/articles/PMC5529746/ /pubmed/28556607 http://dx.doi.org/10.1002/psp4.12199 Text en © 2017 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Gennemark, P Trägårdh, M Lindén, D Ploj, K Johansson, A Turnbull, A Carlsson, B Antonsson, M Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist |
title | Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist |
title_full | Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist |
title_fullStr | Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist |
title_full_unstemmed | Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist |
title_short | Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist |
title_sort | translational modeling to guide study design and dose choice in obesity exemplified by azd1979, a melanin‐concentrating hormone receptor 1 antagonist |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529746/ https://www.ncbi.nlm.nih.gov/pubmed/28556607 http://dx.doi.org/10.1002/psp4.12199 |
work_keys_str_mv | AT gennemarkp translationalmodelingtoguidestudydesignanddosechoiceinobesityexemplifiedbyazd1979amelaninconcentratinghormonereceptor1antagonist AT tragardhm translationalmodelingtoguidestudydesignanddosechoiceinobesityexemplifiedbyazd1979amelaninconcentratinghormonereceptor1antagonist AT lindend translationalmodelingtoguidestudydesignanddosechoiceinobesityexemplifiedbyazd1979amelaninconcentratinghormonereceptor1antagonist AT plojk translationalmodelingtoguidestudydesignanddosechoiceinobesityexemplifiedbyazd1979amelaninconcentratinghormonereceptor1antagonist AT johanssona translationalmodelingtoguidestudydesignanddosechoiceinobesityexemplifiedbyazd1979amelaninconcentratinghormonereceptor1antagonist AT turnbulla translationalmodelingtoguidestudydesignanddosechoiceinobesityexemplifiedbyazd1979amelaninconcentratinghormonereceptor1antagonist AT carlssonb translationalmodelingtoguidestudydesignanddosechoiceinobesityexemplifiedbyazd1979amelaninconcentratinghormonereceptor1antagonist AT antonssonm translationalmodelingtoguidestudydesignanddosechoiceinobesityexemplifiedbyazd1979amelaninconcentratinghormonereceptor1antagonist |